Jamjoom Pharma shareholders also authorized board to distribute interim dividends for 2026.
Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) shareholders approved the transfer of the statutory reserve balance of SAR 67.13 million to retained earnings, based on the annual financial statements for the year ended Dec. 31, 2025. 
The approval came during the extraordinary general meeting (EGM) held on June 15.
According to a Tadawul statement, shareholders also authorized the board of directors to distribute interim dividends on a semi-annual or quarterly basis for 2026.
According to Argaam data, Jamjoom Pharma previously distributed cash dividends of SAR 4 per share for 2025.
Jamjoom Pharma shareholders also authorized board to distribute interim dividends for 2026.
Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) shareholders approved the transfer of the statutory reserve balance of SAR 67.13 million to retained earnings, based on the annual financial statements for the year ended Dec. 31, 2025.
The approval came during the extraordinary general meeting (EGM) held on June 15.
According to a Tadawul statement, shareholders also authorized the board of directors to distribute interim dividends on a semi-annual or quarterly basis for 2026.
According to Argaam data, Jamjoom Pharma previously distributed cash dividends of SAR 4 per share for 2025.
